Ticker Symbol: AKBA
Akebia Therapeutics Inc.
$2.84 - 04-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001517022
Company Profile
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 245 1st St
Website: https://akebia.com/
CEO: John Butler
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.82
Change:
$0.00
(
-0.53%)
Days Range: $0.81 - $0.86
Beta: 1.78
52wk. High: $1.84
52wk. Low: $0.24
Ytd. Change 43.30%
50 Day Moving Average: $1.11
200 Day Moving Average: $1.12
Shares Outstanding: 188313807
Valuation
Market Cap: 15.6B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A